Background
Methods
Search strategies
Study selection and eligibility criteria
Data extraction and validity assessment
Data synthesis and analysis
Results
Study selection and characteristics
Source | Study design, location, years | Number of participants | Main inclusion criteria | Mean age (Years) | Male (%) | Mean BMI (kg/m2) | Mean AHI (events/h) | Mean ESS (points) | OSA assessment |
---|---|---|---|---|---|---|---|---|---|
Milleron et al., 2004 [7] | Prospective cohort, single-center in France, 1991–1999 | 54 | AHI ≥ 15 | 57.3 | 98.1 | 28.3 | 31.2 | NR | Polysomnography |
Cassar et al., 2007 [8] | Retrospective cohort, single-center in US, 1992–2004 | 371 | AHI ≥ 15 | 64.0 | 87.6 | 34.1 | 44.2 | NR | Polysomnography |
Garcia-Rio et al., 2013 [9] | Prospective cohort, single-center in Spain, 2003–2005 | 123 | AHI ≥ 5 | 58.0 | 86.2 | 27.3 | 21.7 | 8.5 | Polysomnography |
Capodanno et al., 2014 [10] | Prospective cohort, single-center in Italy, 2008 | 129 | AHI ≥ 15 | 68.3 | 80.6 | 27.3 | 22.4 | 7 | Portable diagnostic device |
Nakashima et al., 2015 [11] | Prospective cohort, single-center in Japan, 2003–2009 | 95 | AHI ≥ 20 | 71.0a | 77.0a | NR | NR | NR | Polysomnography |
Wu et al., 2015 [12] | Retrospective cohort, single-center in China, 2002–2012 | 295 | AHI ≥ 15 | 55.1 | 84.4 | 29.7 | 42.8 | NR | Polysomnography 72.1%, Portable diagnostic device 27.9% |
Leão et al., 2016 [13] | Prospective cohort, single-center in Portugal, NR | 46 | AHI ≥ 5 | 63.5 | 82.6 | 27.8 | 30.6 | 8.8 | Portable diagnostic device |
Huang et al., 2015 [14] | RCT, parallel, single-center in China, 2009–2012 | 73 | AHI ≥ 15, ESS < 15 | 62.4 | 82.2 | 27.7 | 28.5 | 8.8 | Polysomnography |
Peker et al., 2016 [15] | RCT, parallel, single-center in Sweden, 2005–2010 | 244 | AHI ≥ 15, ESS < 10 | 66.0 | 84.1 | 28.5 | 28.8 | 5.5 | Polysomnography |
Source | Follow-up | Loss to follow-up, % | Outcomes of interest (Primary) | Results | Confounders included in adjusted analysis |
---|---|---|---|---|---|
Milleron et al., 2004 [7] | 86.5 months (median) | 0 | MACE (Cardiovascular death, ACS, hospitalization for heart failure, or revascularization) | Adjusted HR, 0.24 (0.09–0.62) | Age, AHI, BMI, hypertension, and hypercholesterolaemia |
Cassar et al., 2007 [8] | 3 year (median) | 0 | MACE (severe angina, MI, PCI, CABG, stroke, or death | Unadjusted RR, 0.93 (0.79–1.11) | NR |
Garcia-Rio et al., 2013 [9] | 6.5 years (mean) | 2.4% | Recurrent MI | Adjusted HR, 0.16 (0.03–0.76) | Age, sex, body mass index, smoking habit, packs×year, LVEF, diabetes, hypertension, dyslipidemia, metabolic syndrome, smoking cessation and long-term pharmacological treatment |
Capodanno et al., 2014 [10] | 3 years | 0 | MACE (all-cause death, MI, stroke, or repeat revascularization either percutaneous or surgical) | Adjusted HR, 0.18 (0.04–0.78) | BMI, smoking status, previous MI, prior stroke, and LVEF < 40% |
Nakashima et al., 2015 [11] | 4 years (median) | 4.9 | MACE (cardiac death, ACS recurrence, and re-admission for heart failure) | Unadjusted RR, 0.46 (0.21–1.03) | NR |
Wu et al., 2015 [12] | 4.8 years (median) | 1.5 | MACE (death, non-fatal MI, repeat revascularization, stent thrombosis, or stroke) | Adjusted HR, 0.82 (0.53–1.27) | Age, sex, BMI, clinical presentation, smoking, hypertension, type 2 diabetes, dyslipidemia, history of MI, cerebrovascular disease, peripheral arterial disease, renal failure, heart failure (LVEF ≤40%), extent of diseased or treated vessel, adjunctive medical therapy |
Leão et al., 2016 [13] | 75 months (median) | 0 | MACE (death for any cause, MI, and myocardial revascularization | Unadjusted RR, 0.87 (0.31–2.46) | NR |
Huang et al., 2015 [14] | 36 months (median) | 2.4 | MACE (new-onset acute MI, hospitalization for heart failure, need for repeated coronary revascularization, stroke, and death associated with cardiovascular and cerebrovascular disease) | Unadjusted RR, 0.21 (0.03–1.67) | NR |
Peker et al., 2016 [15] | 56.9 months (median) | 0.4 | MACE (repeat revascularization, MI, stroke, and cardiovascular mortality) | Adjusted HR, 0.62 (0.34–1.13) | Age, sex, AHI, BMI, CABG vs. PCI, current smoking, hypertension, diabetes mellitus, acute MI, previous PCI or CABG, pulmonary disease, LVEF |